Sánchez Luna, Manuel RamónBacher, PeterUnnebrink, KristinaMartinez Tristani, MarisolRamos Navarro, Cristina2024-02-062024-02-062020-02-12Sánchez Luna M, Bacher P, Unnebrink K, Martinez-Tristani M, Ramos Navarro C. Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials. J Perinatol. 2020 Aug;40(8):1121-1134. doi: 10.1038/s41372-020-0603-7. Epub 2020 Feb 12. PMID: 32051542; PMCID: PMC7375954.0743-83461476-554310.1038/s41372-020-0603-7https://hdl.handle.net/20.500.14352/99359Findings from previous meta-analyses of randomized clinical trials (RCTs) in premature infants with respiratory distress syndrome (RDS) varied as to whether clinical outcomes differed by type of animal-derived pulmonary surfactant; real-world evidence (RWE) was excluded. We extracted study characteristics and outcomes from full-text articles from a systematic search for studies that compared beractant with poractant alfa for RDS in preterm infants. RWE data were tabulated; RCT data were subjected to meta-analyses. Designs, patient characteristics, and follow-up durations varied widely among studies (4 RWE, 15 RCT). RWE studies with adjusted odds ratios (ORs) found no statistically significant between-treatment differences in outcomes. In RCT meta-analyses, no statistically significant between-treatment differences were observed for death (OR [95% confidence interval], 1.35 [0.98-1.86]), bronchopulmonary dysplasia (1.25 [0.96-1.62]), pneumothorax (1.21 [0.72-2.05]), and air leak syndrome (2.28 [0.82-6.39]). Collectively, outcomes were similar with beractant and poractant alfa in RWE studies and pooled RCTs.engAttribution 4.0 Internationaljournal articlehttps//doi.org/10.1038/s41372-020-0603-732051542https://www.nature.com/articles/s41372-020-0603-7https://pubmed.ncbi.nlm.nih.gov/32051542/open access615.01/.03-053.2Ciencias Biomédicas32 Ciencias Médicas